ClinicalTrials.gg
CompletedNCT05408754PARALELLUpdated Apr 13, 2026

Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLation

An interventional study of Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF. in Atrial Fibrillation, sponsored by Adagio Medical. Completed at 6 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Atrial Fibrillation with a site in Belgium — 34 open to participants now, 52 under way, 1 of them phase 3. Atrial Fibrillation · Belgium.

Enrollment
136th of 160
89 · median 296
Started
2022
with 8 others
No phase
102 of 205
22 open now
Registered
141st of 205
by date

Among the 205 studies in Atrial Fibrillation with a site in Belgium, this one is the 136th largest by enrollment of the 160 interventional ones that give a count, is one of 9 that started in 2022, is one of 102 with no phase, and was the 141st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

34 of the 205 studies in Atrial Fibrillation with a site in Belgium are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Atrial Fibrillation with a site in Belgium, or all of them as a file.
02

Study summary

A prospective, two-arm, multi-center, randomized, open-label, pre-market, First-in-Human clinical study designed to provide safety and performance data regarding the use of the Adagio PFA and PFCA Systems in the treatment of PsAF.

Read the detailed description

Enrolled subjects will be treated (ablation) with the Adagio PFA or PFCA System in a 1:1 randomized fashion.

Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI), and CTI at the discretion and clinical judgment of the investigator.

Data will be collected throughout 12-month follow up period to assess safety and performance of the device. Recurrence of atrial arrhythmias is measured by 12-lead ECGs and 48-hour continuous ECG recording (Holter).

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Pulsed Field Ablation
  • Pulsed Field CryoAblation
  • Persistent AF
  • PFA
  • PFCA
  • AF
  • Adagio Medical
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

IC 1 Male or female between the ages of 18 - 80 years

IC 2 Currently scheduled for an ablation of symptomatic persistent (> 7 days) atrial fibrillation within the past year documented by or Continuous Holter monitoring

IC 3 to at least one class I or III AAD. (Refractory defined as not effective or not tolerated)

IC 4 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study

IC 5 Willingness and ability to give an

Exclusion criteria

Exclusion Criteria:

EC 1 In the opinion of the Investigator, any known to an atrial ablation, TEE, or anticoagulation. Including but not limited to the identification of any atrial thrombus or evidence of sepsis

EC 2 Continuous AF lasting longer than 12-months

EC 3 History of previous left atrial ablation or surgical treatment for AF/AFL/AT

EC 4 AF secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause

EC 5 Structural heart disease as described below:

  1. (LVEF) \< 40% based on most recent TTE
  2. Left atrial size > 55 mm (parasternal long axis view) documented within 6-months of screening
  3. Class III or IV heart failure documented within the previous 12-months
  4. An implanted pacemaker or ICD
  5. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for CABG),
  6. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve
  7. Interatrial baffle, closure device, patch, or PFO occluder
  8. Presence of a left atrial appendage occlusion device
  9. Presence of any pulmonary vein stenting devices
  10. Coronary artery bypass graft (CABG) or PTCA procedure within six (6) months prior to procedure
  11. Unstable angina or ongoing myocardial ischemia
  12. Myocardial infarction within the previous six (6) months prior to procedure
  13. Moderate or severe mitral insufficiency or stenosis based on most recent TTE
  14. Atrial myxoma
  15. Significant congenital anomaly

EC 6 > 40

EC 7 Any previous history of cryoglobulinemia (for those patients randomized to the PFCA arm)

EC 8 History of blood clotting or bleeding disease

EC 9 History of severe requiring use in the previous 12-months

EC 10 History of severe sleep apnea (AHI > 30) not currently treated with a CPAP machine or other mechanical device

EC 11 Stroke or within the last year.

EC 12 Any prior history or current evidence of hemidiaphragmatic paralysis

EC 13 Pregnant or lactating (current or anticipated during study follow-up

EC 14 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study

EC 15 Any other conditions such as, mental illness, addictive disease, terminal illness with a of less than two years, extensive travel away from the research center that may lead to non-compliance with the protocol procedure or follow up

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Pulsed Field Ablation (PFA) group

    PsAF patients treated by PFA

    Device: Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.

  • Experimental
    Pulsed Field CryoAblation (PFCA) group

    PsAF patients treated by PFCA

    Device: Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.

Interventions

  • DeviceAtrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.

    Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator

06

What researchers measure

Primary outcomes

  1. Primary Endpoint for Safety

    Analysis of the proportion of subjects who are free from device/procedure-related Major Adverse Events that occur during or following the ablation procedure

    Time frame: Up to 7 days following the ablation procedure

  2. Primary Procedural Performance Outcome

    Analysis of the evidence of procedural electrical isolation of all pulmonary veins, posterior wall, and bidirectional block (if applicable) across all other ablation lines using the study device.

    Time frame: Procedure

Secondary outcomes

  1. One-Year Safety

    Recording and analysis of all identified serious adverse events and serious adverse device effects through 12 months post-procedure.

    Time frame: 12 months

  2. One-Year Performance

    Proportion of subjects receiving a single ablation procedure who has freedom from any documented left atrial arrhythmia (AF/AFL/AT) lasting longer than 30 seconds following the Blanking Period (3-months ± 14-days post index ablation) using a continuous 48-hour ECG recording through 12 months post-procedure.

    Time frame: 12 months

  3. Procedural Performance - ablation time

    Ablation time defined as the total time for energy delivery to achieve PVI, PWI, and CTI (if applicable)

    Time frame: procedure

  4. Procedural Performance - procedure time

    Total procedure time defined as the time from first venous access to the removal of the catheters from the heart at the end of the procedure

    Time frame: procedure

  5. Procedural Performance - fluoroscopy time

    Procedure fluoroscopy time

    Time frame: procedure

  6. Procedural Performance - intraprocedural PV reconnection rate

    The rate of intraprocedural PV reconnection - defined as confirmed conduction across a PVI line during the 20-minute waiting period to confirm PVI

    Time frame: procedure

  7. Procedural Performance - AAD use

    Recording of the use of AADs in the follow up period beyond a 90-day blanking period

    Time frame: procedure and up to 12-month

  8. Procedural Performance - repeat ablation

    Number of repeat ablations within and following the blanking period

    Time frame: procedure and up to 12-month

07

Study locations

6 sites
  • Onze-Lieve-Vrouwziekenhuis (OLV)
    Aalst, B-9300, Belgium
  • McGill University Health Centre (MUHC), Montreal General Hospital (MGH)
    Montreal, Quebec H3G 1A4, Canada
  • Nemocnice Na Homolce
    Prague, 150 30, Czechia
  • Blackrock Health
    Dublin, A94 E4X7, Ireland
  • St Antonius Ziekenhuis
    Nieuwegein, 3435, Netherlands
  • St George'S University Hospital
    London, SW17 0QT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Oct 2024, 23 months.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 23 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Jun 7, 2022
StartActual
Oct 20, 2022
Primary completionActual
Oct 14, 2024
CompletionActual
Mar 3, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05408754
Lead sponsor
Adagio Medical
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Oct 20, 2022
Primary completion
Oct 14, 2024
Completion
Mar 3, 2025
Last update
Apr 13, 2026

Study contacts

Atul Verma, MD
principal investigator · McGill University Health Centre; Montreal, Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion